Advertisement

Genotype-Based Guidance of Warfarin Dosing Has No Benefit

November 19, 2013

Genotype-Based Guidance of Warfarin Dosing Has No Benefit

  1. Joel M. Gore, MD

Findings from a randomized, double-blind trial in the U.S. do not support genotyping patients for the purpose of tailoring warfarin therapy.

  1. Joel M. Gore, MD

In the Clarification of Optimal Anticoagulation through Genetics (COAG) trial, 1015 U.S. adults were randomized to receive warfarin therapy guided for the first 5 days of dosing either by a genotype-based algorithm in addition to clinical variables or by a control protocol based only on clinical variables. Genotype data were available for 45% of participants before the first warfarin dose and for 94% before the second dose (point-of-care testing was not used). Patients and clinicians were blind to the actual dose of warfarin administered during the first 4 weeks of treatment.

By 4 weeks, the mean percentage of time spent within the therapeutic International Normalized Ratio (INR) range of 2.0 to 3.0 was similar the two groups (about 45%). The two groups also did not differ significantly in mean percentages of time spent below and above the therapeutic INR range or in the elapsed time to first therapeutic INR. Findings persisted regardless of patient sex, number of genetic variants, or predicted daily warfarin dose (<1.0 mg vs. ≥1.0 mg). However, among black patients, the mean percentage of time within the therapeutic INR range was significantly lower in the genotype-guided group than in the control group (35.2% vs. 43.5%). The two groups did not differ significantly in the incidence of adverse events or in time to any INR ≥4.0, major bleeding, or thromboembolism.

Comment

This trial documented no benefit of genotype-guided dosing of warfarin. Given these results and those from European studies, genotype-based guidance of warfarin therapy cannot be recommended. Determining whether particular individuals or subgroups might benefit from the approach will require further study.

  • Disclosures for Joel M. Gore, MD at time of publication Grant / research support NIH; NIH-NHLBI; NSF

Citation(s):

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement